Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Jinsaixing Medical Technology is a prominent biopharmaceutical subsidiary of GeneScience Pharmaceutical (GenSci), focused on the development and commercialization of therapeutic proteins. Based in Beijing, the company serves as a critical R&D and registration hub for GenSci's endocrinology and reproductive health portfolios. Its core business centers on recombinant human growth hormone (rhGH) products, including the well-known water injection brand 'Jinsaixing' used to treat growth disorders in children. The company also supports the development of follicle-stimulating hormones and other recombinant proteins aimed at addressing unmet needs in pediatrics and assisted reproduction. Through its parent organization, Jinsaixing integrates advanced protein expression and PEGylation technologies to improve therapeutic outcomes.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Jinsaixing Medical Technology.